Patents by Inventor Matthew Hebden Porteus

Matthew Hebden Porteus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210317450
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 14, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210009998
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: June 23, 2020
    Publication date: January 14, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 10738305
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180273609
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: November 4, 2016
    Publication date: September 27, 2018
    Applicant: CRISPR Therapeutics AG
    Inventors: Matthew Hebden PORTEUS, Melanie Ruth ALLEN, Chad Albert COWAN, Ante Sven LUNDBERG, Michelle I-Ching LIN, Jeffrey LI, Thao Thi NGUYEN
  • MATERIALS AND METHODS FOR TREATMENT OF HUMAN GENETIC DISEASES INCLUDING HEMOGLOBINOPATHIES
    Publication number: 20180200387
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: February 23, 2016
    Publication date: July 19, 2018
    Inventor: Matthew Hebden Porteus
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180030438
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 1, 2018
    Inventors: Matthew Hebden Porteus, Thomas James Cradick, Gang Bao, Ciaran M. Lee
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180021413
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: February 23, 2016
    Publication date: January 25, 2018
    Inventor: Matthew Hebden Porteus